LONDON and WASHINGTON, March 17 /PRNewswire/ -- Gentag, Inc. (Gentag) announced today that its Board of Directors has engaged VCG & Associates Inc. and Talisman Management Ltd. to assist the Company relating to the sale or license of all or parts of its IP portfolio. VCG & Associates Inc. will provide assistance relating to pharmaceutical and medical diagnostic uses on a global or specific geographic basis. Talisman Management Ltd. will evaluate all other opportunities. Gentag does not anticipate making another announcement in this regard to this matter unless its Board has approved a definitive transaction.
"Gentag has pioneered the concept of combining cell phones with MEMS, RFID and other sensors to create low cost ubiquitous cell phone-sensor networks. Cell phone-sensor networks will broadly impact healthcare, medical diagnostics, Homeland Security and other emerging markets such as 'smart' homes. Currently, the company and its partners are developing innovative low cost monitoring solutions for diabetes, prostate cancer, blood pressure and other common health conditions such as obesity that can be monitored directly by cellular telephones," stated Dr. John P. Peeters, President of Gentag. "With the global adoption of RFID cell phones by all major OEMs and the need to reduce medical costs worldwide our patented solution is creating immediate new market opportunities for the healthcare, IT, telecommunication and defense industries. We look forward to working with VCG & Associates Inc. and Talisman Management Ltd. to assist us in exploring our options and to maximize the full potential of our technology portfolio."
About Gentag, Inc. - Gentag, Inc. is a technology development company focusing on innovative, low-cost, wireless sensor network technologies based on cell phones. The company owns unique intellectual property relating to cell phone-sensor combinations and wireless sensor networks, including
|SOURCE Gentag, Inc.|
Copyright©2009 PR Newswire.
All rights reserved